Search
User Profile
Change
Select your user profile
Article

Roche Digital Pathology Open Environment

Leveraging Roche’s forward-thinking Open Environment

Artificial intelligence technology shows promise in facilitating the analysis and interpretation of pathology images, which can benefit cancer patients through more precise diagnosis and potentially better targeted treatment options.

Open digital pathology environments can break down barriers to allow for rapid technology advances across industry and research partners, which is critical in developing next-generation diagnostic tests.

 

What is the Roche Digital Pathology Open Environment?

 

The Roche Digital Pathology Open Environment  allows software developers to easily integrate their image analysis tools for tumor tissue with Roche’s navify® Digital Pathology, a software designed for the pathologist’s clinical case workflow. The Open Environment allows for the secure exchange and flow of data so that pathologists can access advanced algorithms from third parties alongside Roche’s menu of artificial intelligence-based image analysis tools. This enables software developers globally to distribute their digital products through Roche’s navify Digital Pathology, offering a broader set of diagnostic tools for pathologists and ultimately, the potential for better and faster answers for patients.

Innovation in Digital Pathology

Pathology is undergoing a transformation towards digitization. A workflow solution that can enable pathologists to efficiently complete their daily workload with easy access to new digital tools is essential.

As artificial intelligence tools for clinical use continue to develop, industry and research partners can now leverage Roche’s Digital Pathology Open Environment. This access expands the ability for pathologists to more easily read images from the VENTANA® DP 600 slide scanner and the VENTANA DP 200 slide scanner1 for image analysis algorithm development.

Ultimately, innovative pathology imaging tools for laboratories and healthcare providers can support the selection of the most appropriate targeted therapy option for each patient, advancing Roche’s mission to deliver personalized healthcare.

Become a partner with Roche

Sign up
Our partners

We are excited to share that our first partner algorithms have been available since July 2023.  Roche and PathAI jointly commercialized four PathAI-developed algorithms through navify Digital Pathology in the United States. These PathAI-developed algorithms – the PathAI PD-L1 (28-8) Bundle – are software tools intended for identification and quantification of PD-L1-expressing tumor cells and immune cell within whole slide images (WSI) of formalin-fixed, paraffin-embedded (FFPE) tissue stained with PD-L1 (28-8 clone) and scanned on a VENTANA DP 200 whole slide scanner. In a retrospective study3 published in Modern Pathology, more PD-L1+ patients were identified via PathAI’s algorithm compared to manual scoring, with similar improvements in response and survival. The PathAI- PD-L1 (28-8) Bundle includes algorithms for 4 indications: Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, Non-Small Cell Lung Cancer, and Urothelial Carcinoma. These algorithms are enabled by the Roche Digital Pathology Open Environment, which allows easy integration of PathAI-developed algorithms with navify Digital Pathology. Please note that at this time, these algorithms are For Research Use Only (RUO), not for use in diagnostic procedures.

path-ai-logo
VENTANA slide scanners

VENTANA slide scanners

Digital pathology performance – from start to finish

Explore how high image quality, easy-to-use digital slide scanners from Roche empower pathologists to enhance clinical decisions.

Access to specifications for Roche’s Digital Pathology BIF image file format2

 

With the acceleration of immunotherapy and the development of more complex oncology assays, Roche would like to encourage the development of reliable image analysis algorithms that can provide pathologists with tools to improve efficiency and precision for diagnosis. To that end, Roche is making the specifications of the Roche proprietary BIF file format publicly available.

To view specifications, please agree to our terms and conditions.

Form Successfully Submitted!
Thank you for your submission!
text
close
Terms and Conditions

Register

Submit the form to learn more about becoming a partner

Form Successfully Submitted!
Thank you for your submission!
text
close

You might be interested in

...
    ...

    References and disclaimers

    1. The VENTANA DP 200 slide scanner and the VENTANA DP 600 slide scanner are CE-IVD marked for in-vitro diagnostic use and are available in the U.S. for research use only (RUO); in the US, not for use in diagnostic procedures. Image analysis algorithms developed by third-party entities and their utilisation are the responsibility of the third party provider.
    2. Only for the VENTANA DP 200 slide scanner and the VENTANA DP 600 slide scanner.
    3. Baxi, V., Lee, G., Duan, C. et al. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Mod Pathol 35, 1529–1539 (2022).  https://doi.org/10.1038/s41379-022-01119-2

    VENTANA and NAVIFY are trademarks of Roche.